by Acute Myeloid Leukemia (AML), a type of blood cancer, targets the production of white blood cells in the bone marrow. White blood cells are crucial components of the immune system, and their destruction in AML weakens the body’s defense mechanisms.
Researchers from the Hubbell Lab at the University of Chicago Pritzker School of Molecular Engineering have recently published a study in Blood Advances, proposing a new strategy for developing in-situ cancer vaccines to boost the efficacy of immunotherapies in AML and other blood cancers.
Prof. Jeffrey Hubbell, the Eugene Bell Professor in Tissue Engineering at PME, explained, “Our goal is to create cancer vaccine approaches that are more adaptable and applicable to a broader range of cancers. In essence, we aim to develop a single vaccine that can effectively address multiple cancer types.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
